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Abstract The purpose of the present study is to investi-
gate the effects of krill oil and ﬁsh oil on serum lipids and
markers of oxidative stress and inﬂammation and to eval-
uate if different molecular forms, triacylglycerol and
phospholipids, of omega-3 polyunsaturated fatty acids
(PUFAs) inﬂuence the plasma level of EPA and DHA
differently. One hundred thirteen subjects with normal or
slightly elevated total blood cholesterol and/or triglyceride
levels were randomized into three groups and given
either six capsules of krill oil (N = 36; 3.0 g/day, EPA ?
DHA = 543 mg) or three capsules of ﬁsh oil (N = 40;
1.8 g/day, EPA ? DHA = 864 mg) daily for 7 weeks. A
third group did not receive any supplementation and served
as controls (N = 37). A signiﬁcant increase in plasma
EPA, DHA, and DPA was observed in the subjects sup-
plemented with n-3 PUFAs as compared with the controls,
but there were no signiﬁcant differences in the changes in
any of the n-3 PUFAs between the ﬁsh oil and the krill oil
groups. No statistically signiﬁcant differences in changes in
any of the serum lipids or the markers of oxidative stress
and inﬂammation between the study groups were observed.
Krill oil and ﬁsh oil thus represent comparable dietary
sources of n-3 PUFAs, even if the EPA ? DHA dose in the
krill oil was 62.8% of that in the ﬁsh oil.
Keywords Plasma lipoproteins  Plasma lipids  Dietary
fat  Nutrition, n-3 fatty acids  Lipid absorption 
Phospholipids
Abbreviations
EPA Eicosapentaenoic acid
DHA Docosahexaenoic acid
FA Fatty acid
PL Phospholipids
PUFA Polyunsaturated fatty acid
TG Triglycerides
Introduction
An association between consumption of ﬁsh and seafood
and beneﬁcial effects on a variety of health outcomes has
been reported in epidemiologic studies and clinical trials
[1–5]. These effects are mainly attributed to the omega-3
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dant in ﬁsh and seafood, and in particular to eicosapenta-
enoic acid (EPA) and docosahexaenoic acid (DHA). The
effects of marine n-3 PUFAs on various risk factors of
cardiovascular disease (CVD) are in particular well docu-
mented. In large systematic reviews of the available liter-
ature, consistent reductions in triglyceride (TG) levels
following consumption of n-3 PUFAs have been demon-
strated as well as increases in levels of high-density lipo-
protein (HDL) cholesterol [6, 7]. The net beneﬁcial
effects of these changes have been disputed, although
several large intervention studies indicate that n-3 PUFAs
reduce mortality in patients with high risk of developing
coronary heart disease (CHD) [8]. Moreover, guidelines
published by the American Heart Association for reduc-
ing CVD risk recommend ﬁsh consumption and ﬁsh oil
supplementation based on the acknowledgement that EPA
and DHA may decrease the risk of CHD, decrease sudden
deaths, decrease arrhythmias, and slightly lower blood
pressure [9].
Reports on health beneﬁts have led to increased demand
for products containing marine n-3 PUFAs. Since ﬁsh is a
restricted resource, there is growing interest in exploiting
alternative sources of marine n-3 PUFAs. Antarctic krill
(Euphausia superba) is a rich source of n-3 PUFAs. Krill is
by far the most dominant member of the Antarctic zoo-
plankton community in terms of biomass, which is esti-
mated to be between 125 and 750 million metric tons
(according to the Food and Agriculture Organization of the
United Nations; http://www.fao.org/ﬁshery/species/3393/
en), and thus attractive for commercial harvest. The DHA
content of krill oil is similar to that of oily ﬁsh, but the EPA
content is higher [10]. The overall fatty acid composition
resembles that of ﬁsh. In ﬁsh, the fatty acids are mainly
stored as TG, whereas in krill 30–65% of the fatty acids are
incorporated into phospholipids (PL) [10]. Whether being
esteriﬁed in TG or in PL impacts on the absorption efﬁ-
ciency of FAs into the blood and on effects on serum lipid
levels are issues for discussion. In a study by Maki et al.
[11] comparing the absorption efﬁcacy of n-3 PUFAs from
different sources it was shown that EPA and DHA from
krill oil were absorbed at least as efﬁciently as EPA and
DHA from menhaden oil (TG) [11], and studies in newborn
infants have indicated that fatty acids in dietary PL may be
better absorbed than those from TG [12–14]. Studies
addressing the compartmental metabolism of dietary DHA
have indicated that the metabolic fate of DHA differs
substantially when ingested as TG compared with phos-
phatidylcholine, in terms of both bioavailability of DHA in
plasma and accumulation in target tissues [15]. Only a
limited number of studies addressing health outcomes
following ingestion of krill oil as compared with ﬁsh oil are
currently available, but some of these have shown
promising effects of krill oil on serum lipids and on
markers of inﬂammation and oxidative stress (reviewed in
[10]).
The aim of this study is to investigate the plasma levels
of EPA and DHA, and the effects on serum lipids and on
some biomarkers of inﬂammation, oxidative stress, and
hemostasis, after krill oil and ﬁsh oil administration
in healthy subjects after a 7-week intervention period.
Safety was evaluated based on assessment of hematology
and biochemistry parameters, and registration of adverse
events.
Experimental Procedures
Study Subjects
The 129 subjects included in the study were healthy vol-
unteers of both genders with normal or slightly elevated
total blood cholesterol (\7.5 mmol/L) and normal or
slightly elevated blood triglyceride level (\4.0 mmol/L).
Subjects with body mass index (BMI) [30 kg/m
2, hyper-
lipidemia, hypertension, coronary, peripheral or cerebral
vascular disease were excluded from participating in the
study. No concomitant medication intended to inﬂuence
serum lipid level was permitted. All study subjects were
informed verbally and in writing, and all subjects signed an
informed consent form before entering the study. The study
was approved by the Regional Ethics Committee.
Study Design
The study was an open single-center, randomized, parallel
group designed study. Screening of subjects (N = 149) was
performed at the ﬁrst visit to include subjects that satisﬁed
the eligibility criteria (N = 129). These were randomized
into three study groups. Seven participants were lost before
the baseline visit. The remaining 122 participants were
given either 3 g krill oil daily (N = 41), 1.8 g ﬁsh oil daily
(N = 40) or no supplementation (N = 41) for a period of
7 weeks. A total of 115 participants ﬁnished the study. The
disposition of the subjects is illustrated in Fig. 1. None of
the subjects regularly ate fatty ﬁsh more than once a week
prior to inclusion or during the 7-week intervention period.
None were using cod liver oil or other marine n-3 sup-
plements during the study or at least 2 months prior to
inclusion. All the participants were instructed by a nutri-
tionist to keep their regular food habits during the study.
Study Products
The krill oil capsules contained processed krill oil extracted
from Antarctic krill (Euphausia superba). The product was
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123manufactured by Aker BioMarine ASA. Each capsule
contained 500 mg oil that provided 90.5 mg EPA and
DHA, and a total of 103.5 mg n-3 PUFAs. The capsules
were made of gelatin softened with glycerol. The daily
study dosage was six capsules (each of 500 mg oil). The
comparator omega-3 ﬁsh oil product was manufactured by
Peter Mo ¨ller AS, Oslo, Norway. The daily study dosage
was three capsules each containing 600 mg ﬁsh oil that
provided 288 mg EPA and DHA, and a total of 330 mg n-3
PUFAs. The capsules were made of gelatin softened with
glycerol. The fatty acid proﬁle of the study products is
presented in Table 1. The daily dose of EPA, DHA, and
total n-3 PUFAs in the krill oil and ﬁsh oil groups is pre-
sented in Table 2. The daily EPA ? DHA dose in the krill
oil group was 62.8% of the dosage given in the ﬁsh oil
group. DL-a-tocopheryl acetate (vitamin E), retinyl palmi-
tate (vitamin A), and cholecalciferol (vitamin D) were
added to the product.
Clinical Assessment
Demographic characteristics (gender, age, height, and
weight), concomitant medication, and medical history were
recorded at the screening visit. In addition, all subjects
went through a physical examination to conﬁrm satisfac-
tion of the eligibility criteria.
Changes in concomitant medication from screening,
smoking and alcohol habits, and clinical symptoms before
intake of the study products were also registered.
Serum Lipids and Blood Safety Parameters
Blood from venipuncture was collected after an overnight
fast (C12 h) at baseline and at ﬁnal visit. The subjects were
instructed to refrain from alcohol consumption and from
vigorous physical activity the day before the blood sam-
pling. Serum was obtained from silica gel tubes (BD
Vacutainer), kept at room temperature for at least 30 min
until centrifugation at 1,300 9 g for 12 min at room tem-
perature. Serum analysis of total, low-density lipoprotein
Assessed for eligibility (n=149)
Randomized (n=129)
Allocated to control (n=42)
Received allocated
intervention  (n=41)
Allocated to krill oil (n=44)
Received allocated
intervention  (n=41)
Completed the study (n=37)
Analyzed (n=37)
Excluded from analysis (n=0)
Analyzed (n=36)
Excluded from analysis (n=2)
Analyzed (n=40)
Excluded from analysis (n=0)
Completed the study (n=40)
Allocated to fish oil (n=43)
Received allocated
intervention (n=40)
Completed the study (n=38)
Fig. 1 Disposition of subjects
Table 1 Relative content of fatty acids in the study products
Fatty acid Fish oil (area %) Krill oil (area %)
14:0 3.2 7.4
16:0 7.8 21.8
18:0 2.6 1.3
20:0 0.6 \0.1
22:0 0.4 0.2
16:1n-7 3.9 5.4
18:1n-9, -7, -5 6.1 18.3
20:1n-9, -7 2.0 1.2
22:1n-11, -9, -7 2.5 0.8
24:1n-9 \0.2 0.2
16:2n-4 0.7 0.5
18:2n-6 0.8 1.8
18:3n-6 \0.2 0.2
20:2n-6 0.3 \0.1
20:3n-6 0.2 \0.1
20:4n-6 1.5 0.5
22:4n-6 0.5 \0.1
18:3n-3 0.5 1.0
18:4n-3 1.9 1.6
20:3n-3 \0.2 \0.1
20:4n-3 \0.2 0.7
20:5n-3 27.0 19.0
21:5n-3 1.5 0.5
22:5n-3 4.8 0.5
22:6n-3 24.0 10.9
Other FA 7.2 6.4
Saturated FA 16.0 30.7
Monounsaturated FA 18.0 25.9
n-3 59.0 34.1
n-6 2.9 2.5
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123(LDL), and HDL-cholesterol, TG, apolipoprotein A1, and
apolipoprotein B was performed at the routine laboratory
at Department of Medical Biochemistry at the National
Hospital, Norway using standard methods. Blood samples
for analysis of hematology and serum biochemistry
parameters including hemoglobin, leukocytes, erythro-
cytes, thrombocytes, hematocrit, glucose, calcium, sodium,
potassium, urea, creatinine, alkaline phosphatase, alanine
aminotransferase, bilirubin, albumin, and total protein were
collected and analyzed at the routine laboratory at
Department of Medical Biochemistry at the National
Hospital, Norway using standard methods.
Plasma Fatty Acid Composition
Plasma was obtained from ethylenediamine tetraacetic acid
(EDTA) tubes (BD Vacutainer) kept on ice immediately
and within 12 min centrifuged at 1,300 9 g for 10 min at
10C. Plasma samples were kept frozen at -80C until
analysis. Plasma fatty acid composition was analyzed by
Jurilab Ltd., Finland using a slight modiﬁcation of the
method of Nyyssonen et al. [16]. Plasma (250 lL), fatty
acids, and 25 lL internal standard (eicosane 1 mg/mL in
isopropanol) were extracted with 6 mL methanol–chloro-
form (1:2), and 1.5 mL water was added. The two phases
were separated by centrifugation, and the upper phase was
discarded. To the chloroform phase, 1 mL methanol–water
(1:1) was added, and this extraction was repeated twice.
The chloroform phase was evaporated under nitrogen. For
methylation, the remainder was treated with 1.5 mL sul-
furic acid–methanol (1:50) at 85C for 2 h. The mixture
was diluted with 1.5 mL water and extracted with light
petroleum ether. The fatty acids from the ether phase were
determined using a gas chromatograph (Agilent Technol-
ogies 6890)/mass spectrometer (Agilent Technologies
5973) with electron impact ionization and a HP-5ms cap-
illary column (Hewlett Packard). For retention time and
quantitative standardization, fatty acids purchased from
Nu-Chek-Prep (Elysian, MN, USA) were used. All work
was carried out under a certiﬁed ISO 9001/2000 quality
system.
Plasma a-Tocopherol
Human plasma (100 lL) was diluted with 300 lL 2-pro-
panol containing the internal standard tocol and butylated
hydroxytoluene (BHT) as an antioxidant. After thorough
mixing (15 min) and centrifugation (10 min, 4,000 9 g at
10C), an aliquot of 1 lL was injected from the supernatant
into the high-performance liquid chromatography (HPLC)
system. HPLC was performed with a HP 1100 liquid
chromatograph (Agilent Technologies, Palo Alta, CA,
USA) with a HP 1100 ﬂuorescence detector (emission
295 nm, excitation 330 nm). Tocopherol isomers were
separated on a 2.1 9 250 mm reversed-phase column. The
column temperature was 40C. A two-point calibration
curve was made from analysis of a 3% albumin solution
enriched with known concentration of tocopherols.
Recovery is[95%, the method is linear from 1 to 200 lM
at least, and the limit of detection is 0.01 lM. Relative
standard deviation (RSD) is 2.8% (17.0 lM) and 4.6%
(25.1 lM).
Urinary F2 Isoprostanes
Fasting urine samples were analyzed for 8-iso-prostaglan-
din F2a (8-iso-PGF2a) by a highly speciﬁc and validated
radioimmunoassay as described by Basu [17]. Urinary
levels of 8-iso-PGF2a were adjusted by dividing the 8-iso-
PGF2a concentration by that of creatinine.
Markers of Inﬂammation and Hemostasis
Plasma interleukin-6 (IL-6), tumour necrosis factor-alpha
(TNFa), monocyte chemotactic protein-1 (MCP-1),
thromboxane B2 (TxB2), interferon-gamma (INFc), soluble
E-selectin and P-selectin, soluble intracellular adhesion
molecule-1 (ICAM-1), and vascular cell adhesion mole-
cule-1 (VCAM-1) were determined by Fluorokine
 MAP
kits (R&D Systems, Inc., Minneapolis, MN, USA). Plasma
leukotriene B4 (LTB4) and thromboxane B2 (TxB2) were
assessed as described by Elvevoll et al. [18]. High-sensi-
tivity C-reactive protein (hsCRP) evaluation was per-
formed at the routine laboratory at Department of Medical
Biochemistry at the National Hospital, Norway using
standard method.
Statistics
All continuous variables were summarized by product
group and visit number and described using standard
statistical measures, i.e., number of observations, mean,
Table 2 n-3 fatty acid contents
of the study products
Study product Daily study dose Daily dose
EPA
Daily dose
DHA
Daily dose
EPA ? DHA
Daily dose
n-3 PUFAs
Fish oil 3 capsules (1.8 g oil) 450 mg 414 mg 864 mg 990 mg
Krill oil 6 capsules (3.0 g oil) 348 mg 195 mg 543 mg 621 mg
40 Lipids (2011) 46:37–46
123standard deviation (SD), median, minimum, and maxi-
mum. Absolute and percentagec h a n g ef r o mb a s e l i n et o
the week-7 visit are presented as summary statistics. All
categorical (discrete, including ordinal) variables are
presented in contingency tables showing counts and
percentages for each treatment group at all time points.
Continuously distributed efﬁcacy laboratory parameters
(lipids, EPA, DHA, and docosapentaenoic acid (DPA))
were analyzed by analysis of covariance (ANCOVA)
using the following model: change in parameter value =
baseline value ? treatment ? gender ? age ? error.
Change from baseline to week 7 was used as a depen-
dent variable in the model. A linear model using SAS GLM
with gender as ﬁxed effect, subject as random effect, and
baseline value and age as covariates was applied. A
reduced ANCOVA model with baseline value and treat-
ment was used for the secondary efﬁcacy parameters.
Signiﬁcant treatment effects were analyzed by pairwise
tests. Changes from baseline to end of intervention were
tested by paired t-test.
Results
Subject Characteristics at Baseline
Figure 1 shows the disposition of all subjects. One hundred
ﬁfteen of 129 randomized subjects completed the study.
Withdrawal rates were similar in all three groups (three
withdrawals in the ﬁsh oil group, six withdrawals in the
krill oil group, and ﬁve withdrawals in the control group).
Three subjects discontinued the study due to clinical
symptoms (all in the krill group), three subjects violated
the exclusion criteria (two in the ﬁsh oil group and one in
the krill oil group), and one subject in each group was lost
to follow-up. Two subjects in the control group were
withdrawn due to concomitant treatments, and three sub-
jects withdrew their consent (one subject in the krill oil
group and two subjects in the control group). Clinical
symptoms included symptoms of common cold or gastro-
intestinal symptoms. During database clean-up, it was
detected that two subjects (in the krill oil group) had been
allowed to enter the study although they violated the entry
criteria. They where therefore excluded from the per pro-
tocol subjects. The statistical analyses of efﬁcacy were
performed on the data collected from 113 per protocol
subjects (Fig. 1).
The study groups were comparable in terms of weight,
height, BMI, gender, and age at baseline (Table 3). Vital
signs including systolic and diastolic blood pressure and
heart rate were within normal ranges. More females than
males were included in all study groups.
Fatty Acid Composition in Plasma
Plasma levels of EPA, DHA, and DPA increased signiﬁ-
cantly from baseline to the end of the intervention phase in
the groups receiving ﬁsh oil and krill oil, but not in the
control group. The changes in EPA, DHA, and DPA dif-
fered signiﬁcantly between the subjects supplemented with
n-3PUFAsandthesubjectsinthecontrolgroup,buttherewas
nosigniﬁcantdifferenceinthechangeinanyofthen-3PUFAs
between the ﬁsh oil and the krill oil groups (Table 4).
There were signiﬁcant within-group changes in indi-
vidual FAs from start to end of intervention, but no clear
trends in changes in the plasma FA composition were
apparent in any of the study groups (Table 4).
The level of arachidonic acid (C20:4n-6) increased from
baseline in the krill group, whereas a decrease was
observed in the ﬁsh oil group. The changes in arachidonic
acid between the ﬁsh oil and the krill oil groups, and the
control group differed signiﬁcantly (p = 0.001). Pairwise
comparisons showed that the mean increase in arachidonic
acid in the krill oil group was signiﬁcantly different from
the mean decreases in the ﬁsh oil and control groups, but
there was no signiﬁcant difference between the mean
changes in arachidonic acid level between the ﬁsh oil and
control groups.
Serum Lipids
Small changes in the levels of HDL-cholesterol, LDL-
cholesterol, and TG were observed in all study groups from
start to end of the intervention phase, but only the within-
group increase in LDL-cholesterol seen in the ﬁsh oil
group (p = 0.039) was statistically signiﬁcant. The tests
comparing the differences between the study groups gave
no statistically signiﬁcant results (Table 5). The HDL-
cholesterol/TG ratio and the change from start to end of the
intervention were calculated for all study groups. No sig-
niﬁcant changes in the HDL-cholesterol/TG ratio from start
to end of the interventions were detected in the ﬁsh oil or
Table 3 Demographic information and body measurements
Parameter, mean (SD) Study groups
Fish oil
(N = 43)
Krill oil
(N = 44)
Control
(N = 42)
Age (years) 38.7 (11.1) 40.3 (14.8) 40.5 (12.1)
Height (cm) 171.2 (7.8) 171.3 (8.6) 172.2 (9.4)
Weight (kg) 71.7 (12.0) 69.8 (13.7) 71.7 (12.0)
BMI (kg/m
2) 24.4 (3.0) 23.6 (3.3) 23.9 (3.0)
Gender
Female (n) 34 (79.1%) 31 (70.5%) 28 (66.7%)
Male (n) 9 (20.9%) 13 (29.5%) 14 (33.3%)
Lipids (2011) 46:37–46 41
123Table 4 Fatty acid composition in plasma
Parameter (lmol/L) Treatment N Baseline End of study Change p-Value
a for
change
p-Value
b
between
groups
C14:0 myristic acid Fish oil 40 67.4 ± 57.07 69.4 ± 62.32 2.0 ± 44.05 0.77
Krill oil 36 55.5 ± 32.43 57.8 ± 26.15 2.3 ± 30.93 0.65 0.71
Control 37 60.5 ± 29.25 58.1 ± 38.01 -2.4 ± 35.46 0.69
C15:0 pentadecanoic acid Fish oil 40 18.2 ± 14.42 16.2 ± 8.22 -2.1 ± 12.01 0.28
Krill oil 36 14.7 ± 5.03 15.5 ± 3.69 0.8 ± 4.44 0.30 0.27
Control 37 15.0 ± 5.02 15.0 ± 5.26 0.1 ± 4.32 0.94
C16:0 palmitic acid Fish oil 40 1,661.0 ± 496.5 1,522. ± 339.3 -139.0 ± 409.5 0.038
Krill oil 36 1,548.9 ± 477.9 1,547. ± 260.0 -2.3 ± 414.9 0.97 0.35
Control 37 1,652.7 ± 374.2 1,578. ± 315.6 -74.6 ± 327.7 0.17
C16:1n-7 palmitoleic acid Fish oil 40 67.7 ± 35.41 63.0 ± 33.54 -4.7 ± 27.91 0.29
Krill oil 36 66.1 ± 49.18 61.8 ± 26.56 -4.4 ± 35.91 0.47 0.62
Control 37 68.7 ± 32.98 63.9 ± 35.07 -4.8 ± 28.62 0.31
C17:0 margaric acid Fish oil 40 24.2 ± 8.38 23.9 ± 8.44 -0.3 ± 6.09 0.76
Krill oil 36 22.6 ± 5.85 24.0 ± 5.84 1.4 ± 5.49 0.14 0.089
Control 37 23.3 ± 5.46 21.7 ± 5.84 -1.6 ± 4.85 0.048
C18:0 stearic acid Fish oil 40 580.6 ± 136.6 578.5 ± 130.2 -2.2 ± 133.2 0.92
Krill oil 36 548.5 ± 116.7 568.9 ± 112.6 20.4 ± 91.7 0.19 0.17
Control 37 594.8 ± 103.5 562.4 ± 147.2 -32.4 ± 125.4 0.12
C18:1n-9 oleic acid Fish oil 40 558.9 ± 166.1 516.2 ± 146.8 -42.7 ± 154.0 0.087
Krill oil 36 532.8 ± 198.5 521.8 ± 109.1 -11.0 ± 191.0 0.73 0.71
Control 37 570.2 ± 146.8 547.2 ± 156.1 -23.0 ± 151.9 0.36
C18:2n-6 linoleic acid Fish oil 40 829.3 ± 349.8 779.8 ± 254.5 -49.6 ± 251.3 0.22
Krill oil 36 742.0 ± 214.0 744.2 ± 187.9 2.2 ± 215.8 0.95 0.44
Control 37 812.0 ± 219.6 735.7 ± 212.4 -76.3 ± 167.5 0.0088
C18:3n-3 alpha-linoleic acid Fish oil 40 61.7 ± 17.89 61.9 ± 20.22 0.2 ± 20.95 0.95
Krill oil 36 67.3 ± 25.24 68.4 ± 21.88 1.1 ± 20.08 0.73 0.15
Control 37 68.3 ± 20.40 62.8 ± 22.07 -5.5 ± 19.55 0.094
C20:3n-3 eicosatrienoic acid Fish oil 40 39.6 ± 18.08 33.5 ± 17.97 -6.0 ± 10.00 0.0005
Krill oil 36 39.3 ± 19.20 34.9 ± 13.20 -4.4 ± 13.23 0.054 0.22
Control 37 39.8 ± 18.24 37.7 ± 18.28 -2.1 ± 8.65 0.16
C20:4n-6 arachidonic acid Fish oil 40 192.6 ± 50.0 178.5 ± 45.3 -14.1 ± 29.6 0.0046
Krill oil 36 180.1 ± 52.4 192.1 ± 40.2 12.0 ± 32.8 0.035 0.0010
Control 37 189.8 ± 44.2 182.8 ± 38.0 -7.0 ± 32.3 0.20
C22:0 behenic acid Fish oil 40 21.5 ± 6.05 21.8 ± 6.36 0.4 ± 3.30 0.49
Krill oil 36 20.2 ± 5.29 22.0 ± 6.25 1.9 ± 3.51 0.003 0.040
Control 37 18.9 ± 6.02 18.3 ± 4.83 -0.6 ± 4.07 0.36
C24:0 lignoceric acid Fish oil 40 10.0 ± 4.07 10.3 ± 4.19 0.3 ± 1.71 0.22
Krill oil 36 9.7 ± 2.86 10.4 ± 3.15 0.7 ± 2.04 0.040 0.26
Control 37 8.9 ± 3.37 8.5 ± 3.05 -0.4 ± 2.57 0.40
C24:1n-9 neuronic acid Fish oil 40 18.2 ± 6.88 18.9 ± 6.15 0.6 ± 3.75 0.29
Krill oil 36 16.7 ± 5.99 17.3 ± 5.87 0.6 ± 5.00 0.48 0.17
Control 37 15.7 ± 5.39 16.7 ± 5.70 1.0 ± 5.67 0.30
C20:5n-3 EPA Fish oil 40 31.2 ± 23.11 76.3 ± 36.02 45.2 ± 29.65 \0.0001
Krill oil 36 30.4 ± 21.57 74.9 ± 38.66 44.5 ± 35.21 \0.0001 \0.0001
Control 37 43.9 ± 40.74 37.2 ± 28.64 -6.6 ± 28.58 0.17
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signiﬁcant increase in the HDL-cholesterol/TG ratio. The
test for differences between the study groups gave no
signiﬁcant results (Table 5).
Although the interventions did not signiﬁcantly change
TG levels a reduction was seen in those subjects in the krill
oil group having the highest baseline values (Fig. 2).
The changes in levels of Apo B-100 from baseline to
end of study were minor in all study groups. Moreover,
the test for differences between the study groups in
changes in Apo A1 was not signiﬁcant. However, the
within-group changes of Apo A1 levels from start to end
of the interventions were statistically signiﬁcant in the
krill oil group.
Table 5 Serum lipids and lipoproteins
Parameter Treatment N Baseline End of study Change p-Value
a for
change
p-Value
b
between
groups
HDL-cholesterol (mmol/L) Fish oil 40 1.56 ± 0.384 1.61 ± 0.396 0.05 ± 0.157 0.063
Krill oil 36 1.50 ± 0.368 1.63 ± 0.517 0.13 ± 0.404 0.061 0.50
Control 37 1.59 ± 0.354 1.63 ± 0.395 0.04 ± 0.228 0.29
LDL-cholesterol (mmol/L) Fish oil 40 2.96 ± 0.747 3.09 ± 0.827 0.13 ± 0.377 0.039
Krill oil 36 3.07 ± 0.724 3.16 ± 0.796 0.09 ± 0.390 0.18 0.45
Control 37 2.98 ± 0.824 3.03 ± 0.802 0.05 ± 0.361 0.44
Triglycerides (mmol/L) Fish oil 40 0.95 ± 0.541 0.94 ± 0.542 -0.01 ± 0.462 0.84
Krill oil 36 1.10 ± 0.638 1.01 ± 0.649 -0.09 ± 0.417 0.21 0.65
Control 37 0.92 ± 0.414 0.93 ± 0.523 0.02 ± 0.429 0.82
HDL/triglycerides (%) Fish oil 40 225.8 ± 151.08 216.8 ± 119.33 109.5 ± 44.62 0.19
Krill oil 36 196.9 ± 134.24 228.3 ± 146.62 129.2 ± 68.99 0.016 0.41
Control 37 217.7 ± 138.65 234.4 ± 148.20 113.0 ± 49.28 0.12
Total-cholesterol (mmol/L) Fish oil 40 4.93 ± 0.778 5.13 ± 0.809 0.20 ± 0.424 0.0049
Krill oil 36 4.99 ± 0.815 5.20 ± 0.917 0.21 ± 0.496 0.014 0.78
Control 37 4.95 ± 0.925 5.07 ± 0.861 0.12 ± 0.524 0.18
Apo A1 (mmol/L) Fish oil 40 1.64 ± 0.269 1.68 ± 0.250 0.04 ± 0.130 0.058
Krill oil 36 1.64 ± 0.241 1.73 ± 0.376 0.09 ± 0.267 0.047 0.70
Control 37 1.68 ± 0.272 1.75 ± 0.272 0.07 ± 0.173 0.023
Apo B-100 (mmol/L) Fish oil 40 0.81 ± 0.184 0.80 ± 0.199 -0.01 ± 0.100 0.64
Krill oil 36 0.83 ± 0.208 0.81 ± 0.226 -0.02 ± 0.126 0.35 0.80
Control 37 0.79 ± 0.197 0.78 ± 0.198 -0.01 ± 0.098 0.41
a Test of within-group changes
b Test comparing change from start to end of intervention between the ﬁsh oil, krill oil, and control groups
Table 4 continued
Parameter (lmol/L) Treatment N Baseline End of study Change p-Value
a for
change
p-Value
b
between
groups
C22:6n-3 DHA Fish oil 40 47.0 ± 22.08 70.4 ± 25.70 23.4 ± 16.55 \0.0001
Krill oil 36 44.8 ± 21.36 64.2 ± 26.15 19.4 ± 23.75 \0.0001 \0.0001
Control 37 57.4 ± 30.94 51.3 ± 23.70 -6.1 ± 21.25 0.088
C22:5n-3 DPA Fish oil 40 8.8 ± 3.98 12.7 ± 5.06 3.9 ± 3.24 \0.0001
Krill oil 36 8.2 ± 3.33 11.9 ± 3.56 3.6 ± 3.68 \0.0001 \0.0001
Control 37 9.6 ± 5.09 8.6 ± 3.84 -1.0 ± 3.56 0.090
Total fatty acids Fish oil 40 4,250.7 ± 1,148.1 4,064.6 ± 890.8 -186.0 ± 921.8 0.21
Krill oil 36 3,958.1 ± 983.7 4,045.5 ± 662.5 87.4 ± 810.7 0.52 0.15
Control 37 4,261.3 ± 804.2 4,016.8 ± 774.4 -244.5 ± 685.5 0.037
a Test of within-group changes
b Test comparing change from start to end of intervention between the ﬁsh oil, krill oil, and control groups
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a-Tocopherol is considered an antioxidant, and an increase
in PUFAs may lead to increased oxidative stress. Although
a-tocopherol was added to both supplements, no signiﬁcant
change in levels of a-tocopherol was detected (Supple-
mentary Table). A tendency towards a reduced level of
a-tocopherol was observed in all study groups. F2-iso-
prostanes, formed from free-radical-induced peroxidation
of membrane-bound arachidonic acid, are considered a
reliable biomarker of oxidative stress. However no differ-
ences were observed in urine F2-isoprostane, suggesting
that there was not an increase in oxidative stress. No sig-
niﬁcant changes were observed in levels of hsCRP, markers
of inﬂammation or hemostasis (Supplementary Table).
Discussion
The primary ﬁnding of the present study was that plasma
concentrations of EPA, DPA, and DHA increased signiﬁ-
cantly in both the krill oil and ﬁsh oil groups compared
with the control group following daily supplementation for
7 weeks. There was no statistically signiﬁcant difference
between these two groups in the levels of the increases in
EPA and DHA. Since the subjects in the krill oil group
received 62.8% of the total amount of n-3 PUFAs received
by the subjects in the ﬁsh oil group, these ﬁndings indicate
that the bioavailability of n-3 PUFAs from krill oil (mainly
PL) is as, or possibly more, efﬁcient as n-3 PUFA from ﬁsh
oil (TG). This supports the results of a previous study with
krill oil and menhaden oil in humans [11]. In the study
performed by Maki et al., plasma EPA increased 90% and
DHA increased 51% from baseline levels. In the current
study EPA increased 146% and DHA increased 43% from
baseline levels. The small discrepancy between these two
studies might be related to different levels of EPA and
DHA in the oils used, different treatment time (7 versus
4 weeks), and different dose used (3 g oil versus 2 g). It
has been hypothesized that PL improve the bioavailability
of lipids, which may facilitate absorption of EPA and DHA
from marine PL compared with TG, but the extent to which
this contributes to the efﬁcient absorption observed in the
krill oil group is unknown.
AHA dietary guidelines for long-chain n-3 PUFAs and
ﬁsh for primary prevention of coronary diseases are two
servings of fatty ﬁsh per week [9]. This recommendation
will provide the order of 250–500 mg EPA ? DHA per
day [19]. In the present study we have shown that daily
intake of 3 g krill oil containing 543 mg EPA ? DHA
increases the plasma level of EPA and DHA to the same
extent as intake of ﬁsh oil containing 864 mg EPA ? DHA.
A food-based approach for achieving adequate intake of
n-3 PUFAs is recommended [20]. However, for some
individuals nutritional supplements may be needed, such as
those who do not like ﬁsh or for other reasons choose not to
include ﬁsh in their diet. This study demonstrates that
supplementation with krill oil will be a good source of EPA
and DHA in their daily diet.
Serum TG and HDL-cholesterol have been observed to
be inversely related [21]. Although the metabolic relation
that exists between HDL-cholesterol and TG is not fully
understood, the ratio between TG and HDL-cholesterol has
been shown to be a powerful risk predictor for CHD [22,
23]. In the present study, no statistically signiﬁcant dif-
ferences in HDL-cholesterol, TG or HDL-cholesterol/TG
ratio were observed between the study groups. However,
the change in the HDL-cholesterol/TG ratio in the krill oil
group was statistically signiﬁcant (Table 5). This obser-
vation supports the impression of a more pronounced effect
of krill oil supplementation on HDL-cholesterol and TG
compared with other n-3 PUFA supplements. However, to
verify these effects of krill oil, they should be studied in a
population with elevated blood TG levels and lowered
HDL-cholesterol, i.e., in a population with markers of
metabolic syndrome. The increase in HDL-cholesterol was
slightly higher in the krill oil group than in the ﬁsh oil
group (8.7% versus 3.2%), although not signiﬁcantly so
(p = 0.061). Compared with ﬁsh oil, krill oil contains a
high amount of astaxanthin, which has been indicated to
Fig. 2 Correlation between baseline TG levels and change in TG
levels after 7 weeks of intervention with krill oil or ﬁsh oil
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123increase HDL-cholesterol as well as decrease TG in
humans [24]. Moreover, intake of PL may increase HDL-
cholesterol [25]. The small increase in LDL-cholesterol,
but no effect on HDL-cholesterol, in the ﬁsh oil group is in
accordance with previous ﬁndings [7].
The analysis of the changes in the plasma fatty acid
composition following 7 weeks of intervention with n-3
PUFAs showed that the levels of arachidonic acid and
behenic acid signiﬁcantly increased from baseline in the
krill oil group as compared with the ﬁsh oil and control
groups. Moreover, arachidonic acid was signiﬁcantly
decreased in the ﬁsh oil group. Intake of n-3 PUFAs from
ﬁsh oil can be incorporated in cell PL in a time- and dose-
dependent manner at the expense of arachidonic acid [26].
The explanation and importance of this ﬁnding are not
clear. However, one possible explanation might be that
arachidonic acid is mobilized from the cell membranes to
the blood by EPA and DHA linked to the PL in the krill oil.
However, the changes in plasma arachidonic acid were
small compared with the changes in EPA and DHA, and
there was no signiﬁcant difference in the increase in EPA/
arachidonic acid ratio between the two intervention groups.
TheCRPleveldidnotchangeduringthestudyinanyofthe
studygroups,andnosigniﬁcantchangeswereobservedinthe
other markers of inﬂammation and hemostasis (data not
shown).Thisisinaccordancewithotherswhohaveexamined
the effect of ﬁsh oil among apparently healthy individuals
[27–31]. Moreover, no statistically signiﬁcant differences
were found in a-tocopherol levels and F2-isoprostanes in
urine, suggesting that no oxidative stress occurred.
Thesafetyanalysisrevealednoclearpatternsinthechanges
in any of the hematological or serum biochemical variables,
vital signs or weight that might indicate a relation with
administration of any of the studied products. Clinical symp-
tomsregisteredduringthestudyincludedmainlysymptomsof
common cold or gastrointestinal symptoms. However, one
subject in the ﬁshoil groupexperienced moderate bruises, and
one subject in the krill oil group withdrew from the study
because of an outbreak of rash that was possibly related to
intake of the study products. Safety laboratory parameters and
othersafetyobservationssuchasoccurrenceofadverseevents
indicate that krill oil is well tolerated. There were no apparent
differences in the rate of adverse events or blood safety
parameters between the krill oil, ﬁsh oil or control groups.
In conclusion, the present study shows that n-3 PUFAs
from krill oil in the form of PL are readily and effectively
absorbed after ingestion and subsequently distributed in the
blood. The krill oil supplement is safe and well tolerated.
Krill oil thus represents a valuable source of n-3 PUFAs.
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